Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone

J Atheroscler Thromb. 2006 Oct;13(5):263-4. doi: 10.5551/jat.13.263.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Bezafibrate / adverse effects*
  • Cholesterol, HDL / blood
  • Cholesterol, HDL / drug effects*
  • Diabetes Mellitus, Type 2
  • Drug Therapy, Combination
  • Humans
  • Hyperlipidemias / drug therapy
  • Hypoglycemic Agents / adverse effects*
  • Hypolipidemic Agents / adverse effects*
  • Male
  • Middle Aged
  • Pioglitazone
  • Thiazolidinediones / adverse effects*

Substances

  • Cholesterol, HDL
  • Hypoglycemic Agents
  • Hypolipidemic Agents
  • Thiazolidinediones
  • Pioglitazone
  • Bezafibrate